June 29, 2026
Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe
Eli Lilly and Company has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.








